[Lipids and chronic heart failure]

Area of Science:

• Cardiology and cardiovascular disease research.
• Pharmacological interventions for chronic conditions.
• Epidemiology of heart failure in European populations.

Context:

• Chronic heart failure (CHF) causes have shifted, with ischemic heart disease and hypertension now primary drivers in up to 90% of cases.
• CHF prevalence in Europe is 0.4-2%, translating to a substantial patient burden in countries like the Czech Republic.
• Current pharmacological CHF treatment relies on a combination of five drug classes, including ACE inhibitors.

Purpose:

• To evaluate the impact of simvastatin on mortality in patients with ischemic heart disease, particularly those developing chronic heart failure.
• To assess the role of hypolipidemic therapy in managing heart failure secondary to ischemic heart disease.
• To examine hyperlipoproteinemia prevalence and management post-heart transplantation.

Summary:

• The Scandinavian Simvastatin Survival Study (4S) involving 4,444 patients showed simvastatin reduced CHF incidence (8.3% vs. 10.3%) and mortality (47/184 vs. 73/228) in ischemic heart disease patients.
• Simvastatin treatment led to a 19% relative risk reduction in mortality for heart failure patients, with a number needed to treat (NNT) of 15 over 5 years.
• Hypolipidemic therapy, including statins, is recommended for heart failure patients with ischemic heart disease and is essential for managing hyperlipoproteinemia post-heart transplant.

Impact:

• Findings support integrating hypolipidemic treatment, specifically statins, into standard care for heart failure patients with ischemic heart disease.
• This study highlights the significant benefit of statins in reducing mortality, underscoring their importance in cardiovascular disease management.
• The results inform treatment strategies for hyperlipoproteinemia in heart transplant recipients, emphasizing diet, medication adjustment, and statin therapy.